ArticleClinical drug investigation2018

Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.

Na Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.